Premium
Acute lymphoblastic leukaemia following Hodgkin's disease is associated with a good prognosis
Author(s) -
Narayanan M. N.,
Morgenstern G. R.,
Chang J. C.,
Harrison C. J.,
Ranson M.,
Scarffe J. H.
Publication year - 1994
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.1994.tb04844.x
Subject(s) - etoposide , medicine , disease , chemoradiotherapy , regimen , chemotherapy , myeloid leukaemia , oncology , acute lymphocytic leukemia , myeloid , lymphoblastic leukemia , immunology , gastroenterology , leukemia
Summary. Acute leukaemia, both myeloid and lymphoblastic, in patients treated for Hodgkin's disease (HD) is thought to have a poor prognosis. We report four adults who developed secondary acute lymphoblastic leukaemia (ALL) following chemoradiotherapy for HD. The chromosomal translocation t(4;11) (q21;q23) was found in two patients who received a chemotherapeutic regimen containing the DNA topoisomerase II inhibitor etoposide. Three of the four patients are alive and in unmaintained first remission at 3, 5 and 9 years from diagnosis of ALL, two following autologous bone marrow transplantation. These results suggest that ALL following HD may have a good prognosis when treated aggressively.